Advertisement
Research Article Free access | 10.1172/JCI105578
Department of Medicine, Roswell Park Memorial Institute, New York State Department of Health, Buffalo, N. Y.
†Address requests for reprints to Dr. Joseph E. Sokal, Roswell Park Memorial Institute, Buffalo, N. Y. 14203.
*Submitted for publication October 13, 1966; accepted January 17, 1967.
Supported in part by grant A-1646 from the National Institute for Arthritis and Metabolic Diseases.
Find articles by Sokal, J. in: JCI | PubMed | Google Scholar
Department of Medicine, Roswell Park Memorial Institute, New York State Department of Health, Buffalo, N. Y.
†Address requests for reprints to Dr. Joseph E. Sokal, Roswell Park Memorial Institute, Buffalo, N. Y. 14203.
*Submitted for publication October 13, 1966; accepted January 17, 1967.
Supported in part by grant A-1646 from the National Institute for Arthritis and Metabolic Diseases.
Find articles by Ezdinli, E. in: JCI | PubMed | Google Scholar
Published May 1, 1967 - More info
The isolated perfused rat liver can serve as a bioassay system for glucagon, capable of detecting 10 mμg of this agent. Seven 15-ml plasma specimens obtained from different healthy volunteers after an overnight fast were assayed in this system; glucagon could not be detected in any of them, indicating concentrations significantly below 0.67 mμg per ml in all subjects. The effects of administering small doses of glucagon to patients were consistent with these results; imposition of increments to plasma glucagon concentration below 1 mμg per ml induced distinct and sustained increases in blood glucose.
Observations of the biologic effects of glucagon, together with data on the rate of its inactivation by the liver, suggest that the basal concentration of this hormone in peripheral plasma probably does not exceed 0.1 mμg per ml.